AC Immune Ltd (ACIU) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.63 (-1.87%), Market cap $0.29B, 52-week low–high $1.65 ~ $3.99.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau p
Financial statements, price targets, institutional (13F) holdings and related news for AC Immune Ltd are updated in real time on BlackAll Trade.
AC Immune Ltd trades at $2.63 (-1.87%). Real-time quotes and charts are available on BlackAll Trade.
AC Immune Ltd has a market cap of about $0.29B.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative dise